Immunology

Psoriasis

By mmit_developer
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics....

Rheumatoid Arthritis

By mmit_developer
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics....

Crohn’s Disease

By mmit_developer
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics....

Ulcerative Colitis

By mmit_developer
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics....

Rheumatoid Arthritis

By mmit_developer
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncol...
0 Comments

Meet the Expert: Understanding the Impact of Humira Biosimilars on Market Access

By mmit_developer
Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape....

Immunology Biosimilars: Webcast

By mmit_developer
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts....

Ulcerative Colitis

By mmit_developer
MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira)....

How Will Existing Contracts With AbbVie Shape Payer Strategy Towards Shifting Market Share To Biosimilars?

By mmit_developer
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts....

How Do Payers See The Adalimumab Biosimilar Story Playing Out In 2023?

By mmit_developer
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts....